ATXI:NSD-Avenue Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 0.29

Change

0.00 (-0.72)%

Market Cap

USD 6.37M

Volume

0.37M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

ATXI Stock Forecast & Price:
Based on the Avenue Therapeutics Inc stock forecasts from 0 analysts, the average analyst target price for Avenue Therapeutics Inc is not available over the next 12 months. Avenue Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Avenue Therapeutics Inc is Very Bearish, which is based on 0 positive signals and 7 negative signals. At the last closing, Avenue Therapeutics Inc’s stock price was USD 0.29. Avenue Therapeutics Inc’s stock price has changed by +17.51% over the past week, +2.35% over the past month and -84.69% over the last year.

No recent analyst target price found for Avenue Therapeutics Inc
No recent average analyst rating found for Avenue Therapeutics Inc

About Avenue Therapeutics Inc (ATXI:NSD)

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials ...Read More

Company Website : https://www.avenuetx.com

Address : 1140 Avenue of the America, New York, NY, United States, 10036

Employees : 4

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 0.95

52 Week High : 1.85

Short Ratio : 0.08

52 Week Low : 0.20

Shorted Shares : 30,102

200 Day Moving Average : 0.67

Shorted Shares Previous Month : 77,634

50 Day Moving Average : 0.27

Shares Held By Insiders : 46.91%

Short Percentage : 0.25%

Shares Held by Institutions : 4.80%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-09 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

+4.88 (+1.66%)

 USD73.74B 29.01 20.60
MRNA Moderna Inc

-11.80 (-6.45%)

 USD71.57B 5.79 4.08
REGN Regeneron Pharmaceuticals Inc

-8.48 (-1.34%)

 USD68.73B 12.65 9.34
BNTX BioNTech SE

-12.09 (-7.14%)

 USD40.37B 3.26 2.01
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
SGEN Seagen Inc

-2.73 (-1.53%)

 USD32.89B 55.02 -46.79
RPRX Royalty Pharma Plc

+0.54 (+1.25%)

 USD28.69B 41.21 16.21
ALNY Alnylam Pharmaceuticals Inc

-7.37 (-3.19%)

 USD27.46B N/A -34.32
GMAB Genmab AS

-0.08 (-0.23%)

 USD22.96B 73.23 6.37
BGNE BeiGene Ltd

-4.62 (-2.28%)

 USD21.09B N/A -7.47

ETFs Containing ATXI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -68.29% 16% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -68.29% 16% F 13% F
Trailing 12 Months  
Capital Gain -84.27% 12% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -84.27% 12% F 9% F
Trailing 5 Years  
Capital Gain -95.65% 12% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -95.65% 12% F 3% F
Average Annual (5 Year Horizon)  
Capital Gain -5.31% 44% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.31% 44% F 26% F
Risk Return Profile  
Volatility (Standard Deviation) 66.28% 39% F 20% F
Risk Adjusted Return -8.02% 47% F 38% F
Market Capitalization 6.37M 1% F 1% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.99 21% F 18% F
Price / Cash Flow Ratio -1,699.36 99% A+ 99% A+
EV/EBITDA -0.71 47% F 63% D
Management Effectiveness  
Return on Equity -424.75% 6% F 3% F
Return on Invested Capital -316.45% 4% F 5% F
Return on Assets -179.49% 1% F 0% N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 0.08 98% A+ 97% A+
Short Percent 0.25% 95% A 87% B+
Beta 0.95 65% D 59% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.